During the past decade, Robert A. Moss, MD, FACP, Inc. conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 8 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Robert A. Moss, MD, FACP, Inc." #1 sponsor was "Oncotherapeutics" with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "Point Therapeutics" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Robert A. Moss, MD, FACP, Inc." #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Astex Pharmaceuticals, Inc." with 1 trials as a collaborator, "Bionomics Limited" with 1 trials as a collaborator, "Incyte Corporation" with 1 trials as a collaborator and "Mena, Raul, M.D." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Robert A. Moss, MD, FACP, Inc." are "Multiple Myeloma" (8 trials), "Advanced Prostate Cancer" (1 trials), "Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials) and "Carcinoma, Non-Small Cell Lung" (1 trials). Many other conditions were trialed in "Robert A. Moss, MD, FACP, Inc." in a lesser frequency.

Most popular intervention types in "Robert A. Moss, MD, FACP, Inc." are "Drug" (16 trials), "Biological" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (6 trials), "Lenalidomide" (4 trials), "Elotuzumab" (3 trials), "Pomalidomide" (3 trials) and "Bortezomib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Robert A. Moss, MD, FACP, Inc." are 16 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Robert A. Moss, MD, FACP, Inc.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Robert A. Moss, MD, FACP, Inc., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Robert A. Moss, MD, FACP, Inc., 4 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".